BioNexus Gene Lab Corp (BGLC)

Nasdaq: BGLC · Services-Medical Laboratories · Kuala Lumpur, MY · filing with the SEC since 2019

Full chart Alerts Compare

Grade2.8

◀ Past 3.6● Present 2.8▶ Future 2.1

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of BioNexus Gene Lab Corp

Nine metrics read from its own filings, by tense

Headline grade

2.8/10

◀ Past3.630% of the headline

● Present2.840% of the headline

▶ Future2.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.6/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.9/10

Has it survived what it has been through?

16 warning events since 2019; the latest 2026-03-31.

weight 33% of this tense · 9th percentile among 27 sector filers · read for itself

From the record

BioNexus Gene Lab Corp's filings since 2019 show 16 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2025-04-30); an auditor change (8-K item 4.01, the latest 2020-10-08); a late-report notice (Form NT 10-K or NT 10-Q, 10 times, the latest 2026-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

4.7/10

What has it actually done, year after year?

+66.2% a year over 8 filed years; profitable in 3 of 8.

weight 45% of this tense · 47th percentile among 23 sector filers · read for its customers

From the record

BioNexus Gene Lab Corp's 8 filed years say what it did: revenue went from $212 thousand in fiscal 2018 to $7 million in fiscal 2025, up 66.2% a year; it rose in 2 of 7 years; the deepest fall was 44% from fiscal 2021 to fiscal 2025; net income was positive in 3 of 8 of those years (its annual reports).

What it rests on

revenue growth over the filed span66.2%top 7% of its family
the share of years revenue rosebottom 2% of its family
the share of filed years with a profittop 24% of its family
the deepest fall from a revenue peak44.4%bottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.6/10

How has it treated the people who own it?

SI estimate 5.6/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 21 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 21 members with one.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: family median, 21 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioNexus Gene Lab Corp's shareholder treatment is put at 5.6 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 21 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.8/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

5.5/10

Is it financially healthy right now?

ROE -35%: lost 35¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar.

weight 33% of this tense · 54th percentile among 25 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioNexus Gene Lab Corp lost about 35 cents for every dollar of shareholders' money, and gross profitability: its products earned about 12 cents per dollar of everything the company owns. Leverage: it owed about 7 cents per dollar of assets (the filed statements).

What it rests on

what it owes per dollar of assetstop 10% of its family
return on equitybottom 26% of its family
gross profit against assetsbottom 47% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.9/10

How strong is its position in its industry?

bottom 19% of 24 in its family; net margin -40.2%.

weight 45% of this tense · 19th percentile among 24 sector filers · read for its customers

From the record

BioNexus Gene Lab Corp's standing among 24 graded names in its industry family: revenue of $7 million in fiscal 2025 ranks in the bottom 20% by size; a net margin of -40.2% ranks in the bottom 27%; revenue growth of -12.1% a year over the last 3 filed years ranks in the bottom 11% (its annual reports).

What it rests on

revenue against the family$7.4Mbottom 20% of its family
net margin-40.2%bottom 27% of its family
three-year revenue growth-12.1%bottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

0.5/10

What are the people in charge doing?

bottom 5% of 17 in its family for leadership; chief executive since 2026.

weight 22% of this tense · 5th percentile among 17 sector filers · read for its shareholders

From the record

BioNexus Gene Lab Corp's leadership, from its insiders' filings and its current reports: the chief executive on the record is Tan, Lee Su-Leng (Chief Executive Officer, as filed), filing under that title since 2026-07-31, 3 months (bottom 3% of its family); the 5 officers and directors filing in the last fifteen months have been on the record a median of 3 months (bottom 3%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 9%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge5 in three years among 5 peoplebottom 9% of its family
the median years the people in charge have filed4 monthsbottom 3% of its family
the chief executive's years on the record4 monthsbottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

2.1/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.3/10

How much room does it have to grow?

bottom 33% of 24 in its family for room to expand.

weight 22% of this tense · 33rd percentile among 24 sector filers · read for itself

From the record

BioNexus Gene Lab Corp's room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against no long-term debt tagged leaves 26.9% of its assets as net cash, top 29% of its family; cash from operations less capital spending is -25.3% of revenue (bottom 35%); a gross margin of 14.6% (bottom 22%); research spending of 0.7% of revenue (bottom 3%) (its annual report).

What it rests on

cash less debt against assets26.9%top 29% of its family
cash from operations less capital spending against revenue-25.3%bottom 35% of its family
gross margin14.6%bottom 22% of its family
research spending against revenue0.7%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

1.5/10

What could actually drive growth from here?

bottom 15% of 23 in its family for growth drivers.

weight 45% of this tense · 15th percentile among 23 sector filers · read for its customers

From the record

BioNexus Gene Lab Corp's growth drivers, from the filed years to fiscal 2025: revenue grew -12.1% a year over the last three filed years against 66.2% over all 8, slowing (bottom 2% of its family); the newest year grew -21.9% (bottom 7%); research spending grew -4% a year (bottom 36%) (its annual reports). BioNexus Gene Lab Corp tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-78.2 points a yearbottom 2% of its family
the newest year's revenue growth-21.9%bottom 7% of its family
three-year growth of research spending-4.0%bottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

2.3/10

Did its newest year beat what its own record pointed to?

bottom 23% of 20 in its family for expectations against reality.

weight 33% of this tense · 23rd percentile among 20 sector filers · read for its shareholders

From the record

BioNexus Gene Lab Corp's newest year against its own record: revenue of $7 million in fiscal 2025 came in 16.3% below the $9 million its prior three years' pace pointed to (bottom 33% of its family); net income of $3 million against a prior three-year average of $2 million (bottom 23%); a net margin of -40.2% against -15.7% before (bottom 13%) (its annual reports).

What it rests on

revenue against the prior three years' pace-16.3%bottom 33% of its family
net income against the prior three years' average-95%bottom 23% of its family
net margin against its prior average-24.5 pointsbottom 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BGLC · research, not advice